Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

European Journal of Cancer

Volumn 50, Issue 16, 2014, Pages 2791-2801

  Graham, Christopher N ^a   Hechmati, Guy ^b   Hjelmgren, Jonas ^b   De Liège, Frédérique ^c   Lanier, Julie ^c   Knox, Hediyyih ^a   Barber, Beth ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b AMGEN INC   (United States)

^c Value and Access Amgen SAS   (France)

Author keywords

Bevacizumab; Colorectal cancer; Cost effectiveness; Panitumumab

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FEVER; FAINTNESS; FEBRILE NEUTROPENIA; GASTROESOPHAGEAL REFLUX; HUMAN; INFECTION; INTESTINE PERFORATION; LUNG EMBOLISM; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; POPULATION MODEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEPSIS; TREATMENT DURATION; TUMOR GROWTH; URINARY TRACT INFECTION; VOMITING; WILD TYPE; AGED; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ECONOMICS; EXON; FEMALE; HEALTH CARE COST; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PROBABILITY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXONS; FEMALE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; LEUCOVORIN; MALE; MARKOV CHAINS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84924984580     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.08.016     Document Type: Article

References (36)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 6 2013 1374 1403 10.1016/j.ejca.2012.12.027
2. M. Chauvenet, V. Cottet, C. Lepage, V. Jooste, J. Faivre, and A.M. Bouvier Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population BMC Cancer 30 11 2011 282 10.1186/1471-2407-11-282
3. H.J. Schmoll, E. Van Cutsem, and A. Stein ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 10 2012 2479 2516
4. H. Brenner, A.M. Bouvier, and R. Foschi Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study Int J Cancer 131 7 2012 1649 1658 10.1002/ijc.26192
5. R.L. Jamison, J.H. Donohue, and D.M. Nagorney Hepatic resection for metastatic colorectal cancer results in cure for some patients Arch Surg 132 1997 505 510
6. E. Van Cutsem, B. Nordlinger, A. Cervantes ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 21 suppl. 5 2010 v93 7 10.1093/annonc/mdq222
7. J.Y. Douillard, K.S. Oliner, and S. Siena Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
8. L.S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J.L. Canon, and J.R. Hecht PEAK: a randomized, Multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 2014 [Epub ahead of print]
9. PEAK [NCT00819780] clinical study report. Data on file. Thousand Oaks, CA, USA: Amgen Inc.
10. D. Lawrence, M. Maschio, and K.J. Leahy Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wildtype metastatic colorectal cancer (mCRC) J Med Econ 16 2013 1387 1398
11. L. Hedden, H. Kennecke, and D. Villa Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada Eur J Cancer 48 2012 1969 1976 10.1016/j.ejca.2012.01.012
12. A. Vijayaraghavan, M.B. Efrusy, B. Göke, T. Kirchner, C.C. Santas, and R.M. Goldberg Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany Int J Cancer 131 2 2012 438 445 10.1002/ijc.26400
13. P.R. Blank, H. Moch, T.D. Szucs, and M. Schwenkglenks KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective Clin Cancer Res 17 19 2011 6338 6346 10.1158/1078-0432.CCR-10-2267
14. T. Shiroiwa, Y. Motoo, and K. Tsutani Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer Mol Diagn Ther 14 6 2010 375 384 10.2165/11587610-000000000-00000
15. R. Adam, V. Delvart, and G. Pascal Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 4 2004 644 657 [discussion 657-8]
16. A.B. Benson 3rd, T. Bekaii-Saab, and E. Chan Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines J Natl Comp Cancer Netw 11 2 2013 141 152 [quiz 152]
17. P.F. Engstrom National Comprehensive Cancer Network Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy Pharmacotherapy 28 11 Pt 2 2008 18S 22S 10.1592/phco.28.11-supp.18S
18. Ministère des Affaires Sociales et de la Santé. [Arrêté du 22 février 2013 fixant pour l'année 2013 les éléments tarifaires mentionnés aux I et IV de l'article L. 162-22-10 du code de la sécurité sociale et aux IV et V de l'article 33 modifié de la loi de financement de la sécurité sociale pour 2004. J O N°50.] February 28, 2013. Available at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000027115074&dateTexte=&categorieLien=id [accessed 31.01.14].
19. Ministère des Affaires Sociales et de la Santé. [Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l'article L. 162-16-6 du code de la sécurité sociale. Jorf N°0145 25 Juin 2013. AFSS1315947V.] May 30, 2013; p. 10498.
20. HEVA. HEOR analysis of PMSI database; 2012.
21. M. Peeters, T. Price, and A. Cervantes Randomized phase 3 study of panitumumab with FOLFIRI vs. FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713 10.1200/JCO.2009.27.6055
22. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544
23. Qiagen. KRAS RGQ PCR Kit (therascreen KRAS test); 2013. Available at: http://www.qiagen.com/Landing-Pages/therascreen-KRAS-Test-USA-Subgroups [accessed 31.01.14].
24. ameli.fr [Internet]. Tarifs des consultations des médecins correspondants (applicables au 26 mars 2012). Available at: http://www.ameli.fr/assures/soins-et-remboursements/combien-serez-vous-rembourse/consultations/les-consultations-en-metropole/dans-le-cadre-du-parcours-de-soins-coordonnes-rhone.php?&page=3 [accessed 19.02.13].
25. Classification Commune des Actes Médicaux [Internet]. Version 31; 2013. Available at: http://www.ameli.fr/fileadmin/user-upload/documents/CCAM-V31.pdf [accessed 31.01.14].
26. G. Mickisch, M. Gore, B. Escudier, G. Procopio, S. Walzer, and M. Nuijten Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib Br J Cancer 102 1 2010 80 86 10.1038/sj.bjc.6605417
27. J.Y. Douillard, P. Tilleul, and M. Ychou Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting Oncology 72 3-4 2007 248 254 10.1159/000113016
28. A. Vergnenegre, R. Corre, and H. Berard Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study J Thorac Oncol 6 1 2011 161 168
29. I. Durand-Zaleski, A. Vainchtock, and O. Bogillot L'utilisation de la base nationale PMSI pour déterminer le coût d'un symptôme: le cas de la neutropénie fébrile J Econ Med 25 5-6 2007 269 280
30. E. Remak, and L. Brazil Cost of managing women presenting with stage IV breast cancer in the United Kingdom Br J Cancer 91 1 2004 77 83
31. Curtis L. Unit costs of health and social care 2012. Canterbury: Personal Social Services Research Unit; 2012. Available at: http://kar.kent.ac.uk/32408/1/full-with-covers.pdf [accessed 31.01.14].
32. EQ-5D data from the PRIME trial [ NCT00364013 ]. Data on file. CA, USA: Amgen Inc.
33. P. Dolan Modeling valuations for EuroQol health states Med Care 35 11 1997 1085 1108
34. Haute Autorité de santé, Department of Economics and Public Health Assessment. Choices in methods for economic evaluation. October 2012. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices-in-methods-for-economic-evaluation.pdf [accessed 31.01.14].
35. A. Fourrier-Réglat, D. Smith, and M. Rouyer Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort Target Oncol 2013 10.1007/s11523-013-0296-3 [Epub ahead of print]
36. T.J. Price, M. Peeters, and T.W. Kim Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study Lancet Oncol 15 2014 569 579